Coeptis Therapeutics (NASDAQ:COEP) Trading Down 2.1% - Here's What Happened

Key Points

• Shares of Coeptis Therapeutics fell about 2.1% to $11.06 (intraday low $10.85) on light volume of ~24,612 shares, about 48% below the stock's average daily volume, and trading remains below the 50- and 200-day moving averages.
• Analyst sentiment is negative—Weiss Ratings reissued a "sell (e+)" and the MarketBeat consensus rating is Sell.
• The company has a market cap of ~$68.8M and reported negative EPS (-$0.12) with an extreme negative net margin (-803.96%) and ROE (-110.89%), though it shows strong liquidity (quick/current ratio 4.16) and very low debt (debt-to-equity 0.01).

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) were down 2.1% on Monday . The stock traded as low as $10.85 and last traded at $11.06. Approximately 24,612 shares traded hands during trading, a decline of 48% from the average daily volume of 47,321 shares. The stock had previously closed at $11.30.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of "Sell".

Coeptis Therapeutics Price Performance

The firm has a market capitalization of $68.79 million, a price-to-earnings ratio of -3.71 and a beta of -0.48. The stock's 50-day moving average price is $12.49 and its 200 day moving average price is $14.29. The company has a quick ratio of 4.16, a current ratio of 4.16 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $0.86 million for the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%.

Institutional Investors Weigh In On Coeptis Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new position in Coeptis Therapeutics during the fourth quarter worth approximately $259,000. State Street Corp grew its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company's stock valued at $382,000 after buying an additional 6,962 shares in the last quarter. Steward Partners Investment Advisory LLC grew its holdings in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company's stock valued at $71,000 after buying an additional 2,500 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company's stock worth $600,000 after acquiring an additional 4,721 shares during the last quarter. Finally, Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics in the 3rd quarter worth $140,000. Institutional investors and hedge funds own 13.88% of the company's stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.